The $125 billion question: how will the ACA affect cancer survivors?
In 2010, the total cost of cancer care in the United States reached $125 billion. Cancer patients are also living longer today, which is further increasing the cost of their continued care. As the health insurance exchanges have opened and heated debate about the Affordable Care Act (ACA) continues, many questions remain, including the $125 billion question: “How will the ACA affect the most expensive disease: cancer?”
You’ve got a friend
Kim McGaughey is a four-time cancer survivor. In 2008, she was diagnosed with stage 1B cervical cancer and stage 4 breast cancer. After beating her cervical cancer and getting her breast cancer under control, Kim was blindsided by a cervical cancer recurrence in 2011 that had metastasized to her lungs. Now, in 2014, Kim has just finished chemotherapy for her second recurrence of cervical cancer. For most, a journey like this would make you understandably negative – but not Kim. She and a group of her closest friends turned her daunting, 8-hour chemotherapy infusion treatments into celebrations, which they aptly named “chemo parties.”
Chat on the current state of cancer treatment and research
This past Tuesday ABC News hosted a Twitter chat with the American Association for Cancer Research (AACR) on the current state of cancer following the release of the Cancer Progress Report 2014. Steven R. Grossman, M.D., Ph.D., deputy director of Massey Cancer Center, provided expert commentary as Dr. Richard Besser, ABC News Chief Health/Medical Editor, posed a series of questions and discussion topics.
Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer
Inflammation has been shown to be a driving force behind many chronic diseases, especially liver cancer, which often develops due to chronic inflammation caused by conditions such as viral hepatitis or alcoholism and has relatively few effective treatment options. Now, scientists at Virginia Commonwealth University Massey Cancer Center have demonstrated for the first time in preclinical studies that blocking the expression of a gene known as astrocyte elevated gene-1 (AEG-1) halts the development and progression of liver cancer by regulating inflammation. This research could impact not only the treatment of liver cancer, but many inflammation-associated diseases.
Making progress against breast cancer
In honor of Breast Cancer Awareness Month, learn about the many ways VCU Massey Cancer Center is making progress in the prevention and treatment of breast cancer and ways in which you can celebrate and support these advances. A National Cancer Institute-designated cancer center, VCU Massey is helping to lead and shape the nation’s fight against breast and other cancers.
New non-invasive technique could revolutionize the imaging of metastatic cancer
Bioluminescence, nanoparticles, gene manipulation – these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors. In preclinical animal models of metastatic prostate cancer, scientists at Virginia Commonwealth University Massey Cancer Center, VCU Institute of Molecular Medicine and Johns Hopkins Medical Institutions have provided proof-of-principle of a new molecular imaging approach that could revolutionize doctors’ ability to see tumors that have metastasized to other sites in the body, including the bones.